Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 12/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | F12 | P00748 | 1/20 | 0.34 |
| ▸ | SCD | O00767 | 1/20 | 0.34 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24469811 | 0.93 | P2RX3 (0.39) | P2RX3HDAC1HDAC6F12SCD | |
| SCHEMBL24469837 | 0.85 | P2RX3 (0.41) | P2RX3HDAC1HDAC6USP30LMNA | |
| SCHEMBL24484041 | 0.83 | EPHX2 (0.33) | SCDLMNA | |
| SCHEMBL24469924 | 0.81 | HTR2C (0.34) | HDAC1HDAC6 | |
| SCHEMBL24470065 | 0.78 | P2RX3 (0.41) | P2RX3 | |
| SCHEMBL22830598 | 0.76 | GPR119 (0.37) | P2RX3HDAC1HDAC6JAK2JAK1 | |
| SCHEMBL22845221 | 0.76 | GCGR (0.40) | P2RX3HDAC1HDAC6LMNA | |
| SCHEMBL22845402 | 0.75 | P2RX3 (0.43) | P2RX3HDAC1HDAC6 | |
| SCHEMBL24469807 | 0.74 | P2RX3 (0.43) | P2RX3HDAC1HDAC6F12LMNA | |
| SCHEMBL24469917 | 0.73 | HDAC1 (0.36) | P2RX3HDAC1HDAC6JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2022115384-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | P2RX3 3237/4885HDAC1 47/4885HDAC6 12/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | P2RX3 3237/4885HDAC1 47/4885HDAC6 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.